Understanding epidermal growth factor receptor mutation (EGFRm) testing in patients (pts) with non-small cell lung cancer (NSCLC) in a large community oncology network.

@inproceedings{Nadler2018UnderstandingEG,
  title={Understanding epidermal growth factor receptor mutation (EGFRm) testing in patients (pts) with non-small cell lung cancer (NSCLC) in a large community oncology network.},
  author={Eric Nadler and Ancilla W. Fernandes and Melissa Pavilack and Susan Amirian and Jamyia Clark and Jennifer R. Frytak},
  year={2018}
}
9Background: EGFR TKI therapy improves outcomes in pts with EGFRm+ NSCLC. NCCN guidelines recommend EGFRm testing for pts with NSCLC. Testing patterns and predictors of documented EGFRm testing were studied in a real-world setting. Methods: Adult pts with stage IV NSCLC treated from 1/1/2012 to 8/31/2017, identified from the iKnowMed (US Oncology Network) EHR were analyzed. Rates of documented EGFRm testing were calculated. Multivariable stepwise logistic regression analysis was conducted to… CONTINUE READING